Browse All

Current Filters

CLEAR FILTER x

TITLE

Patient Reported Attitudes Towards Multiple Sclerosis Treatment

Author:Cronin, Dianna   

Session Name:P7: Multiple Sclerosis: Patient Experience and Patient-reported Outcomes in Multiple Sclerosis and Related Diseases  

Topic:Multiple Sclerosis  

Program Number:P7.011  

Author Institution:myhealthteam, San Francisco , CA  

Comparing First-line Natalizumab and Ocrelizumab Use for the Treatment of Multiple Sclerosis: A Komodo Health Claims Database Study

Author:Kaplan, Jeffrey   Beenstock, Dana   Belkin, Martin   Crayton, Heidi   Eckstein, Christopher   Fredericks, Ruth   Bian, Boyang   Belviso, Nicholas   Ni, Daphne   Rutledge, Danette   

Session Name:P7: Multiple Sclerosis: Disease-modifying Therapies: Real-world Evidence and Adverse Events 1  

Topic:Multiple Sclerosis  

Program Number:P7.012  

Author Institution:Kansas City MS Center, Overland Park, KS  Linda E. Cardinale Multiple Sclerosis Center, Freehold, NJ  Michigan Institute for Neurological Disorders, Farmington Hills, MI  MS Center of Greater Washington, Vienna, VA  Duke University, Durham, NC  St. Dominic Neuroscience Center, Jackson, MS  Biogen, Cambridge, MA  

Real-world-data on Ofatumumab as First-line Treatment in Early RMS (AIOLOS study)

Author:Nelles, Gereon   Pfeuffer, Steffen   Wagner, Carola   

Session Name:P7: Multiple Sclerosis: Disease-modifying Therapies: Real-world Evidence and Adverse Events 1  

Topic:Multiple Sclerosis  

Program Number:P7.013  

Author Institution:Neuromed-Campus, Cologne, Germany  University Hospital Giessen, Giessen, Germany  Novartis Pharma GmbH, Nuremberg, Germany  

ENABLE: The First Phase 4 Observational Study for Patients with Relapsing MS Treated with Ublituximab in Real World Clinical Setting

Author:Fox, Edward   Parker, Jackie   Bodhinathan, Karthik   Sportelli, Peter   Miskin, Hari   Hersh, Carrie   

Session Name:P7: Multiple Sclerosis: Disease-modifying Therapies: Real-world Evidence and Adverse Events 1  

Topic:Multiple Sclerosis  

Program Number:P7.014  

Author Institution:TG Therapeutics, Round Rock, TX  TG Therapeutics, Morrisville, NC  TG Therapeutics, Lexington, MA  TG Therapeutics, New York, NY  Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV  

Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-world Observational Survey (ENAMOR)

Author:Fox, Edward   Sportelli, Peter   Miskin, Hari   Garner, Chris   

Session Name:P7: Multiple Sclerosis: Disease-modifying Therapies: Real-world Evidence and Adverse Events 1  

Topic:Multiple Sclerosis  

Program Number:P7.015  

Author Institution:TG Therapeutics, Round Rock, TX  TG Therapeutics, Stuart, FL  TG Therapeutics, New York, NY  TG Therapeutics, Ozark, MO